Premium
Non‐metastatic osteosarcoma of the extremities in children aged 5 years or younger
Author(s) -
Abate Massimo Eraldo,
Longhi Alessandra,
Galletti Stefano,
Ferrari Stefano,
Bacci Gaetano
Publication year - 2010
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.22567
Subject(s) - medicine , osteosarcoma , amputation , blood cancer , chemotherapy , adjuvant chemotherapy , surgery , cancer , pathology , breast cancer
Background The occurrence of high‐grade osteosarcoma is rare in children aged 5 years or younger and only limited series or case reports have been described. Methods The records of patients aged 5 years or younger with non‐metastatic high‐grade osteosarcoma of the extremities treated with surgery and adjuvant or neo‐adjuvant chemotherapy at Rizzoli Institute between 1972 and 1999 were retrospectively evaluated in relation to gender, primary tumor site, histological subtype, surgical treatment, chemotherapy‐induced tumor necrosis, 5‐ and 10‐year event‐free survival (EFS), and rate of local recurrence. Data were compared to patients aged 6–40 years entered with the same diagnosis and over the same time interval. Results Data from 20 patients were collected. Comparing these data with those from 1,106 patients 6–40 years of age only two main differences resulted: the younger group showed a higher rate for fibroblastic subtype ( P < 0.01) and for amputation surgery ( P < 0.01). Among the two groups, no statistical difference was observed for the 5‐year EFS (60% vs. 53.8%; P = 0.6) and 10‐year EFS (60% vs. 52.1%; P = 0.5). The rate of local recurrence was 5.0% and 5.4%. Conclusions These findings suggest that in non‐metastatic osteosarcoma of the extremities outcome and clinical characteristics are similar among children 5 years of age or younger and older patients. However, in the younger group we have observed a significant higher rate of fibroblastic subtype as well as a significant higher rate of mutilating surgery. Pediatr Blood Cancer. 2010;55:652–654. © 2010 Wiley‐Liss, Inc.